| Date Checked | 2025-12-21 23:26:11 |
|---|---|
| Graham Number | (PB)nan vs (PE)71.74 |
| Over / Under Value Percentage | 0.00% vs nan% |
| Dividend Yield | 2.85% |
| Dividend Date | 2026-02-17 |
| Symbol | ABBV |
| AssetType | Common Stock |
| Name | AbbVie Inc |
| Description | AbbVie Inc is a leading American biopharmaceutical company, established in 2013 from a spin-off of Abbott Laboratories. The company specializes in the research, development, and commercialization of advanced therapies in immunology, oncology, virology, and neuroscience. With a robust pipeline of innovative treatments, AbbVie is committed to addressing some of the world's most challenging health issues and is recognized for its blockbuster immunology drug, Humira. AbbVie continues to strengthen its portfolio through strategic acquisitions and collaborations, positioning itself as a formidable player in the global biopharmaceutical landscape. |
| CIK | 1551152 |
| Exchange | NYSE |
| Currency | USD |
| Country | USA |
| Sector | HEALTHCARE |
| Industry | DRUG MANUFACTURERS - GENERAL |
| Address | 1 NORTH WAUKEGAN ROAD, NORTH CHICAGO, IL, UNITED STATES, 60064-6400 |
| OfficialSite | https://www.abbvie.com |
| FiscalYearEnd | December |
| LatestQuarter | 2025-09-30 |
| MarketCapitalization | 404218544000 |
| EBITDA | 29519000000 |
| PERatio | 174.59 |
| PEGRatio | 0.412 |
| BookValue | -1.495 |
| DividendPerShare | 6.56 |
| EPS | 1.31 |
| RevenuePerShareTTM | 33.72 |
| ProfitMargin | 0.04 |
| OperatingMarginTTM | 0.355 |
| ReturnOnAssetsTTM | 0.0959 |
| ReturnOnEquityTTM | 1.38 |
| RevenueTTM | 59643998000 |
| GrossProfitTTM | 42622001000 |
| DilutedEPSTTM | 1.31 |
| QuarterlyEarningsGrowthYOY | -0.887 |
| QuarterlyRevenueGrowthYOY | 0.091 |
| AnalystTargetPrice | 243.55 |
| AnalystRatingStrongBuy | 7 |
| AnalystRatingBuy | 13 |
| AnalystRatingHold | 9 |
| AnalystRatingSell | 0 |
| AnalystRatingStrongSell | 1 |
| TrailingPE | 174.59 |
| ForwardPE | 16.39 |
| PriceToSalesRatioTTM | 6.78 |
| PriceToBookRatio | 50.46 |
| EVToRevenue | 7.88 |
| EVToEBITDA | 36.73 |
| Beta | 0.352 |
| 52WeekHigh | 243.06 |
| 52WeekLow | 160.33 |
| 50DayMovingAverage | 227.78 |
| 200DayMovingAverage | 204.35 |
| SharesOutstanding | 1767385000 |
| SharesFloat | 1763938000 |
| PercentInsiders | 0.105 |
| PercentInstitutions | 75.170 |
| ExDividendDate | 2026-01-16 |
| naga | 1 |
| etoro | 1 |
| dateChecked | 2025-12-21 23:26:11 |
| fresh | 1 |